tiprankstipranks
Trending News
More News >
HemoGenyx Pharmaceuticals Plc (GB:HEMO)
LSE:HEMO
Advertisement

HemoGenyx Pharmaceuticals Plc (HEMO) Price & Analysis

Compare
20 Followers

HEMO Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

7.70%92.30%
7.70%
Insiders
Mutual Funds
― Other Institutional Investors
92.30% Public Companies and
Individual Investors

HEMO FAQ

What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 124.00p and its highest was 1199.60p in the past 12 months.
    What is HemoGenyx Pharmaceuticals Plc’s market cap?
    HemoGenyx Pharmaceuticals Plc’s market cap is £6.05M.
      When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
      HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 25, 2025 which is in 66 days.
        How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
        Currently, no data Available
        Is HemoGenyx Pharmaceuticals Plc overvalued?
        According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does HemoGenyx Pharmaceuticals Plc pay dividends?
          HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
          What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
          HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
          HemoGenyx Pharmaceuticals Plc has 4,593,539 shares outstanding.
            What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
            Currently, no hedge funds are holding shares in GB:HEMO

            Company Description

            HemoGenyx Pharmaceuticals Plc

            Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
            Similar Stocks
            Company
            Price & Change
            Follow
            ImmuPharma
            Oxford BioDynamics
            Fusion Antibodies Plc
            Arecor Therapeutics PLC
            Aptamer Group Plc
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis